Putting Amivantamab Plus Lazertinib Into Practice
Panelists discuss key takeaways from the analysis of long-term results, noting that these findings may influence their recommendations for first-line regimens in EGFR-mutant metastatic non–-small cell lung cancer. They highlight how they engage patients in discussions about treatment options, considering efficacy and safety, while addressing remaining unmet needs in this therapeutic area.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
